As of 2024-12-13, the Intrinsic Value of Trillium Therapeutics Inc (TRIL.TO) is
0.79 CAD. This TRIL.TO valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 23.33 CAD, the upside of Trillium Therapeutics Inc is
-96.60%.
The range of the Intrinsic Value is 0.65 - 0.85 CAD
TRIL.TO Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
0.65 - 0.85 |
0.79 |
-96.6% |
| DCF (Growth 10y) |
0.85 - 0.68 |
0.79 |
-96.6% |
| Fair Value |
-3.76 - -3.76 |
-3.76 |
-116.12% |
| P/E |
(23.63) - (35.44) |
(29.53) |
-226.6% |
| EPV |
(3.30) - (4.39) |
(3.85) |
-116.5% |
| DDM - Stable |
(3.35) - (8.09) |
(5.72) |
-124.5% |
| DDM - Multi |
(0.08) - (0.15) |
(0.10) |
-100.4% |
TRIL.TO Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
2,607.01 |
| Beta |
1.96 |
| Outstanding shares (mil) |
111.75 |
| Enterprise Value (mil) |
2,475.02 |
| Market risk premium |
4.74% |
| Cost of Equity |
14.25% |
| Cost of Debt |
5.00% |
| WACC |
9.62% |